麻豆传媒

Pediatrics >

RSV

News, opinions and meeting coverage in pediatrics.

A computer rendering of RSV viruses.

A Framework to Communicate With Pregnant Patients About the RSV Vaccine

A values-based decision-making framework is key

A photo of a box of Abrysvo over a photo of a pregnant woman receiving a vaccination.

CDC Advisors Endorse Maternal RSV Vax to Protect Newborns

Vast majority of infants will not need monoclonal antibody if mom has received the vaccine

A computer rendering of respiratory syncytial virus particles.

What to Know About New Tools to Fight RSV

Two vaccines and a monoclonal antibody aim to bring down the burden of RSV

FDA APPROVED RSV prefusion F protein vaccine (Abrysvo) over a photo of a male nurse preparing to vaccinate a pregnant woman.

RSV Vaccine Approved for Use in Pregnancy to Protect Infants

Prescribing info has warning about the potential risk for premature birth

A photo of the syringes and packaging of Beyfortus 100 mg/ml and 50 mg/ml.

CDC Advisors Back Therapeutic to Prevent RSV in Infants

Unanimous support for monoclonal antibody for infants and high-risk toddlers as well

FDA APPROVED nirsevimab (Beyfortus) over a computer rendering of respiratory syncytial viruses

New Drug Approved for Preventing RSV in Newborns, Tots

Nirsevimab indicated for all infants, and for kids up to 2 years at high risk

FDA ADCOMM nirsevimab over a computer rendered cutaway of an RSV virus.

Antibody for Infant RSV Prevention to Face FDA Panel

Nirsevimab shot also a possibility for some at-risk toddlers

A computer rendering of a monoclonal antibody.

Monoclonal Antibodies Linked to Reduced RSV Burden in Young Kids

Meta-analysis of 14 RCTs showed significant reductions in infection, hospitalization

A photo of a nurse wearing a surgical mask while tending to an infant suffering from respiratory syncytial virus.

Our Pediatric 'Immunity Debt' Is Really an 'RSV Debt'

The virus is now collecting what it is owed

A computer rendering of the respiratory syncytial virus

What Caused RSV to Roar Back During COVID?

Multinational study pinpoints the most important drivers of the seasonal illness

2021 YEAR IN REVIEW respiratory syncytial virus over a computer rendering of the virus.

Year in Review: Respiratory Syncytial Virus

Vaccine development for older adults continued apace, virus roared back in kids

FDA Advisers Turn Down New RSV Drug

WASHINGTON -- An FDA advisory committee recommended Wednesday that the agency not approve the investigational drug motavizumab to treat respiratory infections, deciding that it didn't offer any advantages over the drug already on the market, and that it may be more dangerous.